// App-Quantinova.ai

S198 : BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Andrea Patriarca

  • Claire Harrison

  • Prithviraj Bose

  • Francesca Palandri

  • Timothy Devos

  • Francesco Passamonti

  • Gabriela Hobbs

  • Moshe Talpaz

  • Alessandro Vannucchi

  • Jean-Jacques Kiladjian

  • Srdan Verstovsek

  • Ron Hoffman

  • Mohamed E Salama

  • Dong Chen

  • Pietro Taverna

  • Alex Chang

  • Gozde Colak

  • Sandra Klein

  • Vikas Gupta

Medical Centers

  • Constellation Pharmaceut

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • MD Anderson Cancer Center ,Houston,Verenigde Staten

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Department of Translational Medicine, University of Eastern Piedmont, Ospedale Maggiore della Carità Novara, Novara, Italy

  • Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX

  • Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Mayo Clinic, Rochester, MN

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Guy's and St

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven,Leuven,Belgio

  • University of Insubria,Varese,Italia

  • MD Anderson Cancer Center ,Houston,Verenigde Staten

  • Mayo Clinic,Rochester,Stati Uniti

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven,Leuven,Belgio

  • University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven,Leuven,Belgio

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Princess Margaret Cancer Centre and University of Toronto,...

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • IRCCS Azienda ospedaliero-universitaria di Bologna,Istituto di Ematologia 'Seràgnoli',Bologna,Italia

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Mayo Clinic,Rochester,Estados Unidos

  • Hôpital Saint-Louis, Université de Paris, INSERM,Paris,Frankrijk

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Hematology,Mayo Clinic,Rochester, MN,États-unis

  • Hematology

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • Division of Hematology and Oncology,Massachusetts General Hospit

  • IRCCS Azienda ospedaliero-universitaria di Bologna,Istituto di Ematologia 'Seràgnoli',Bologna,Italia

  • Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Insubria,Varese,Italia

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Hôpital Saint

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Mayo Clinic, Rochester, United States

  • Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Tisch Cancer Institute, Icahn Sc

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • IRCCS Azienda ospedaliero-universitaria di Bologna,Istituto di Ematologia 'Seràgnoli',Bologna,Italia

  • Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX

  • Hematology,Mayo Clinic,Rochester, MN,Vereinigte Staaten

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,New York,Vereinigte Staaten

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Leukemia Department, Univers

  • University of Insubria,Varese,Italien

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • University of Insubria,Varese,Италия

  • Department of Translational Medicine, University of Eastern Piedmont, Ospedale Maggiore della Carità Novara, Novara, Italy

  • University of Insubria,Varese,Italia

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

  • Department of Translational Medicine, University of Eastern Piedmont, Ospedale Maggiore della Carità Novara, Novara, Italy

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Univer

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Hematology,Mayo Clinic,Rochester, MN,Vereinigte Staaten

  • Univ. of Insubria, Varese, Italy

  • University Hospitals Leuven and Laboratory of Molecular Immunology (Rega

  • Guy's and St Thomas' NHS Foundation Trust,London,Royaume-uni

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • 1.MD Anderson Cancer Center, Houston, TX

  • IRCCS Azienda ospedaliero-universitaria di Bologna,Istituto di Ematologia 'Seràgnoli',Bologna,Italia

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • University of Insubria,Varese,Italia

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • University of Michigan Comprehensive Cancer Center,Ann Arbor, MI,Vereinigte Staaten

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Locations

  • United States

  • Italy

  • United Kingdom

  • Belgium

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

  • CPI-0610

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02158858

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved